Archive: November, 2015

 

 

Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

Northridge, CA, USA and Cambridge, United Kingdom, 24 November 2015.

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK.

Read more about Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK.

Read more about Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical Trial Research Agreement with the University of Adelaide for the purpose of conducting a Phase I clinical study. 

Read more about AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections

Nexvet Announces Positive Results From NV-01 Pivotal Study in Dogs With Osteoarthritis

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced positive results from its pivotal safety and efficacy study of NV-01, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with osteoarthritis in dogs. 

Read more about Nexvet Announces Positive Results From NV-01 Pivotal Study in Dogs With Osteoarthritis

Jeremy Curnock Cook spoke to Sky News Business 27 Oct 2015

Jeremy Curnock Cook on Sky News Business (The Perrett Report) Oct 27, 2015.

Read more about Jeremy Curnock Cook spoke to Sky News Business 27 Oct 2015